3--4--dihydroxyaurone and Diabetes-Mellitus

3--4--dihydroxyaurone has been researched along with Diabetes-Mellitus* in 1 studies

Other Studies

1 other study(ies) available for 3--4--dihydroxyaurone and Diabetes-Mellitus

Article	Year
Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis. European journal of medicinal chemistry, 2017, Apr-21, Volume: 130 Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC Topics: Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Benzofurans; Cells, Cultured; Diabetes Mellitus; Drug Discovery; Humans; Inhibitory Concentration 50; Islets of Langerhans; Protective Agents; Protein Serine-Threonine Kinases; Structure-Activity Relationship	2017

Article

Year

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis.

European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC

Topics: Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Benzofurans; Cells, Cultured; Diabetes Mellitus; Drug Discovery; Humans; Inhibitory Concentration 50; Islets of Langerhans; Protective Agents; Protein Serine-Threonine Kinases; Structure-Activity Relationship

2017